Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
نویسندگان
چکیده
The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. efficacy and safety of as compared with adalimumab, tumor necrosis factor α inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic drugs are unclear.
منابع مشابه
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
OBJECTIVE To evaluate the long-term effectiveness and tolerability of adalimumab in the treatment of psoriatic arthritis (PsA). METHODS Patients with PsA who completed a 24-week, double-blind study of adalimumab versus placebo were eligible to enroll in an open-label extension study and receive adalimumab 40 mg subcutaneously every other week for up to an additional 120 weeks. At the time of ...
متن کاملBULLETIN BOARD Latest data on adalimumab therapy for ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis
Results recently presented at the Annual refractory to them over time. Adalimumab Of those who had experienced no response European Congress of Rheumatology in Paris, France, suggests that adalimumab is safe and effective in patients with ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis who are not responding to anti-TNF therapy. In a recent series of studies, adalimumab was...
متن کاملEvaluation of COVID-19 incidence in psoriatic patients receiving Adalimumab
Background: Adalimumab is a highly human monoclonal antibody that binds to tumor necrosis factor, a key proinflammatory cytokine pathogenic in psoriasis. It considers an influential factor in controlling moderate to severe psoriasis. This study aimed to evaluate the impact of Adalimumab on COVID-19 incidence in patients with psoriasis. Methods: This cross-sectional study was performed at Baqiy...
متن کاملComparing bone mineral density in rheumatoid arthritis and psoriatic arthritis
Background: Changes in patients’ bone mineral density (BMD) is one of the problems in patients with rheumatoid arthritis, which can be due to the use of corticosteroid drugs to reduce patients' symptoms or due to the aging process in patients. In this study, we decided to compare BMD in patients with psoriatic arthritis and rheumatoid arthritis. Methods: This study as a cross-sectional descrip...
متن کاملEtanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
BACKGROUND Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment. OBJECTIVE To determine the clinical effectiveness, safety and cost-effectiveness of these biologic agents in the treatment of active and progressive PsA. DATA SOURCES Systematic reviews ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The New England Journal of Medicine
سال: 2021
ISSN: ['0028-4793', '1533-4406']
DOI: https://doi.org/10.1056/nejmoa2022516